Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB-WT) Long-Term Deferred Tax (2023 - 2025)

Nuvation Bio (NUVB-WT) has disclosed Long-Term Deferred Tax for 3 consecutive years, with $245.0 million as the latest value for Q4 2025.

  • Quarterly Long-Term Deferred Tax rose 0.98% to $245.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $245.0 million through Dec 2025, up 0.98% year-over-year, with the annual reading at $245.0 million for FY2025, 0.98% up from the prior year.
  • Long-Term Deferred Tax for Q4 2025 was $245.0 million at Nuvation Bio, up from $242.6 million in the prior quarter.
  • The five-year high for Long-Term Deferred Tax was $245.0 million in Q4 2025, with the low at $101.4 million in Q4 2023.
  • Average Long-Term Deferred Tax over 3 years is $196.3 million, with a median of $242.6 million recorded in 2024.
  • The sharpest move saw Long-Term Deferred Tax skyrocketed 139.21% in 2024, then rose 0.98% in 2025.
  • Over 3 years, Long-Term Deferred Tax stood at $101.4 million in 2023, then surged by 139.21% to $242.6 million in 2024, then grew by 0.98% to $245.0 million in 2025.
  • According to Business Quant data, Long-Term Deferred Tax over the past three periods came in at $245.0 million, $242.6 million, and $101.4 million for Q4 2025, Q4 2024, and Q4 2023 respectively.